CoChat
Sign Up
Cited by 20Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

The pathway to secondary prevention of Alzheimer's disease

Open access
McDade, Eric, Bednar, Martin M., Brashear, H. Robert, Miller, David S., Maruff, Paul, Randolph, Christopher, Ismail, Zahinoor, Carrillo, Maria C. +3 more·2020·Alzheimer's & Dementia: Translational Research & Clinical Interventions
DOI 10.1002/trc2.12069PMC PMC7453146
Open this paper in CoChat — free accountOpen PDF

Abstract

Alzheimer's disease (AD) is a continuum consisting of a preclinical stage that occurs decades before symptoms appear. As researchers make advances in investigating the continuum, the importance of developing drugs for secondary prevention is garnering increased discussion. For efficacious drug development for secondary prevention it is important to define what are the earliest biological stages of AD. The Alzheimer's Association Research Roundtable convened November 27 to 28, 2018 to focus on pre‐clinical AD. This review will address the biological approach to defining pre‐clinical AD, detection, identification of at‐risk individuals, and lessons learned from trials such as A4 and TOMMORROW.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/trc2.12069

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a community-based autopsy cohort, 8% of A+T−N cases versus 68% of A+T+N cases were associated with incident dementia in the last 5 years of life.

    “One community-based autopsy cohort study of amyloid (A), tauopathy (T), and neurodegeneration (N) markers found only 8% of (A+T -[N]) compared t68% of (A+T+[N]) were associated with incident dementia in the last 5 years of life.(441)”

    From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [441]

    The ‘Defining Preclinical AD’ section explains the A, T, and (N) markers, but does not report outcomes from a community-based autopsy cohort. Searches for the 8% and 68% figures and for incident dementia in the last five years of life found no passage addressing that comparison. (LLM, conf=0.72)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 84

  1. [2]Perl DP. Neuropathology of Alzheimer's disease. Mt Sinai J Med. 2010; 77(1): 32‐ 42. 20101720 PMC2918894
  2. [3]Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States. Alzheimers Dement. 2018; 14: 121‐ 129. 29233480 PMC5803316
  3. [4]Brookmeyer R, Abdalla N. Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 2018; 14: 981‐ 988. 29802030 PMC6097953
  4. [5]Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med. 2013; 368: 1326‐ 1334. 23550670 PMC3959992
  5. [6]Jack CR, Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010; 9: 119‐ 128. 20083042 PMC2819840
  6. [7]Jack CR, Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12: 207‐ 216. 23332364 PMC3622225
  7. [8]Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012; 367: 795‐ 804. 22784036 PMC3474597
  8. [9]Fleisher AS, Chen K, Quiroz YT, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross‐sectional study. JAMA Neurol. 2015; 72: 316‐ 324. 25580592 PMC4355261
  9. [10]McDade E, Wang G, Gordon BA, et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018; 91: e1295‐ e1306. 30217935 PMC6177272
  10. [11]Fagan AM, Xiong C, Jasielec MS, et al. Longitudinal change in CSF biomarkers in autosomal‐dominant Alzheimer's disease. Sci Transl Med. 2014; 6: 226ra230. PMC4038930 24598588
  11. [12]Scholl M, Maass A, Mattsson N, et al. Biomarkers for tau pathology. Mol Cell Neurosci 2018; 97: 18‐ 33. 30529601 PMC6584358
  12. [13]Chertkow H, Feldman HH, Jacova C, Massoud F. Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. Alzheimers Res Ther. 2013; 5: S2. 24565215 PMC3981054
  13. [15]Kinnunen KM, Cash DM, Poole T, et al. Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study. Alzheimers Dement. 2018; 14: 43‐ 53. 28738187 PMC5751893
  14. [16]Suarez‐Calvet M, Kleinberger G, Araque Caballero MA, et al. STREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med. 2016; 8: 466‐ 476. 26941262 PMC5120370
  15. [17]Weston PSJ, Poole T, Ryan NS, et al. Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology. 2017; 89: 2167‐ 2175. 29070659 PMC5696646
  16. [18]Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer's Disease Neuroimaging I. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017; 74: 557‐ 566. 28346578 PMC5822204
  17. [19]Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019; 25: 277‐ 283. 30664784 PMC6367005
  18. [21]Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7: 280‐ 292. 21514248 PMC3220946
  19. [22]Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014; 6: 228fs213. PMC4049292 24648338
  20. [24]Bateman RJ, Benzinger TL, Berry S, et al. The DIAN‐TU Next Generation Alzheimer's prevention trial: adaptive design and disease progression model. Alzheimers Dement. 2017; 13: 8‐ 19. 27583651 PMC5218895
  21. [25]O'Bryant SE, Mielke MM, Rissman RA, et al. Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement. 2017; 13: 45‐ 58. 27870940 PMC5218961
  22. [26]O'Bryant SE, Gupta V, Henriksen K, et al. Guidelines for the standardization of preanalytic variables for blood‐based biomarker studies in Alzheimer's disease research. Alzheimers Dement 2015; 11: 549‐ 560. 25282381 PMC4414664
  23. [28]de Rojas I, Romero J, Rodriguez‐Gomez O, et al. Correlations between plasma and PET beta‐amyloid levels in individuals with subjective cognitive decline: the Fundacio ACE Healthy Brain Initiative (FACEHBI). Alzheimers Res Ther 2018; 10: 119. 30497535 PMC6267075
  24. [30]Martinez G, Vernooij RW, Fuentes Padilla P, Zamora J, Bonfill Cosp X, Flicker L. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2017; 11: CD012216. 29164603 PMC6486090
  25. [31]Martinez G, Vernooij RW, Fuentes Padilla P, Zamora J, Flicker L, Bonfill Cosp X. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2017; 11: CD012884. 29164602 PMC6486287
  26. [32]Martinez G, Vernooij RW, Fuentes Padilla P, Zamora J, Flicker L, Bonfill Cosp X. 18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2017; 11: CD012883. 29164600 PMC6485979
  27. [33]Sundaram GS, Dhavale DD, Prior JL, et al. Fluselenamyl: a novel benzoselenazole derivative for PET detection of Amyloid Plaques (Abeta) in Alzheimer's disease. Sci Rep 2016; 6: 35636. 27805057 PMC5090206
  28. [34]Ossenkoppele R, Rabinovici GD, Smith R, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 2018; 320: 1151‐ 1162. 30326496 PMC6233630
  29. [35]Lemoine L, Leuzy A, Chiotis K, Rodriguez‐Vieitez E, Nordberg A. Tau positron emission tomography imaging in tauopathies: the added hurdle of off‐target binding. Alzheimers Dement (Amst) 2018; 10: 232‐ 236. 29780868 PMC5956931
  30. [36]Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid‐neuropathology in a population‐based autopsy study. Neurology 2003; 60: 652‐ 656. 12601108
  31. [37]Blennow K, Mattsson N, Scholl M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci 2015; 36: 297‐ 309. 25840462
  32. [40]Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta‐amyloid 1‐42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98‐ 106. 22213792
  33. [41]Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid beta‐amyloid 1‐42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 2007; 78: 461‐ 464. 17098843 PMC2117838
  34. [42]Janelidze S, Zetterberg H, Mattsson N, et al. CSF Abeta42/Abeta40 and Abeta42/Abeta38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol 2016; 3: 154‐ 165. 27042676 PMC4774260
  35. [43]Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta‐analysis. Lancet Neurol 2016; 15: 673‐ 684. 27068280
  36. [44]Mattsson N, Scholl M, Strandberg O, et al. (18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease. EMBO Mol Med 2017; 9: 1212‐ 1223. 28743782 PMC5582410
  37. [45]Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012; 18: 552‐ 556. 22492131
  38. [46]Skillback T, Rosen C, Asztely F, Mattsson N, Blennow K, Zetterberg H. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt‐Jakob disease: results from the Swedish Mortality Registry. JAMA Neurol 2014; 71: 476‐ 483. 24566866
  39. [48]Lewczuk P, Ermann N, Andreasson U, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. Alzheimers Res Ther 2018; 10: 71. 30055655 PMC6064615
  40. [49]Gisslen M, Price RW, Andreasson U, et al. Plasma concentration of the neurofilament light Protein (NFL) is a biomarker of CNS injury in HIV infection: a Cross‐Sectional Study. EBioMedicine 2016; 3: 135‐ 140. 26870824 PMC4739412
  41. [50]Burnham SC, Rowe CC, Baker D, et al. Predicting Alzheimer disease from a blood‐based biomarker profile: A 54‐month follow‐up. Neurology 2016; 87: 1093‐ 1101. 27534714
  42. [53]Mielke MM, Hagen CE, Wennberg AMV, et al. Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic Study On Aging. JAMA Neurol 2017; 74: 1073‐ 1080. 28692710 PMC5710182
  43. [54]Thompson AGB, Luk C, Heslegrave AJ, et al. Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt‐Jakob disease, and tau correlates with rate of disease progression. J Neurol Neurosurg Psychiatry 2018; 89: 955‐ 961. 29487167 PMC6109239
  44. [55]Zetterberg H, Wilson D, Andreasson U, et al. Plasma tau levels in Alzheimer's disease. Alzheimers Res Ther 2013; 5: 9. 23551972 PMC3707015
  45. [56]Mielke MM, Hagen CE, Xu J, et al. Plasma phospho‐tau181 increases with Alzheimer's disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography. Alzheimers Dement 2018; 14: 989‐ 997. 29626426 PMC6097897
  46. [57]Hye A, Lynham S, Thambisetty M, et al. Proteome‐based plasma biomarkers for Alzheimer's disease. Brain 2006; 129: 3042‐ 3050. 17071923
  47. [59]Donohue MC, Sperling RA, Petersen R, et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA 2017; 317: 2305‐ 2316. 28609533 PMC5736301
  48. [60]Hassenstab J, Chasse R, Grabow P, et al. Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning. Neurobiol Aging 2016; 43: 23‐ 33. 27255812 PMC4893196
  49. [61]Roberts RO, Aakre JA, Kremers WK, et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population‐based setting. JAMA Neurol 2018; 75: 970‐ 979. 29710225 PMC6142936
  50. [62]Harrington KD, Dang C, Lim YY, et al. The effect of preclinical Alzheimer's disease on age‐related changes in intelligence in cognitively normal older adults. Intelligence 2018; 70: 22‐ 29.
  51. [63]Insel PS, Weiner M, Mackin RS, et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology 2019; 93: e322‐ e333. 31289148 PMC6669933
  52. [64]Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement 2014; 10: 844‐ 852. 24798886 PMC4317324
  53. [65]Amariglio RE, Buckley RF, Mormino EC, et al. Amyloid‐associated increases in longitudinal report of subjective cognitive complaints. Alzheimers Dement (N Y) 2018; 4: 444‐ 449. 30258973 PMC6153378
  54. [66]Slot RER, Verfaillie SCJ, Overbeek JM, et al. Subjective Cognitive Impairment Cohort (SCIENCE): study design and first results. Alzheimers Res Ther 2018; 10: 76. 30081935 PMC6080529
  55. [67]van Harten AC, Mielke MM, Swenson‐Dravis DM, et al. Subjective cognitive decline and risk of MCI: the Mayo Clinic Study of Aging. Neurology 2018; 91: e300‐ e312. 29959257 PMC6070384
  56. [68]Rabin LA, Smart CM, Amariglio RE. Subjective cognitive decline in preclinical Alzheimer's disease. Annu Rev Clin Psychol 2017; 13: 369‐ 396. 28482688
  57. [69]Caselli RJ, Langlais BT, Dueck AC, et al. Personality changes during the transition from cognitive health to mild cognitive impairment. J Am Geriatr Soc 2018; 66: 671‐ 678. 29341070 PMC5906173
  58. [70]Wise EA, Rosenberg PB, Lyketsos CG, & Leoutsakos JM. Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer's Coordinating Centers volunteers. Alzheimer'sDementia. 2019; 11: 333‐ 339. PMC6476801 31024987
  59. [71]McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263‐ 269. 21514250 PMC3312024
  60. [72]Cieslak A, Smith EE, Lysack J, Ismail Z. Case series of mild behavioral impairment: toward an understanding of the early stages of neurodegenerative diseases affecting behavior and cognition. Int Psychogeriatr 2018; 30: 273‐ 280. 29017626
  61. [74]Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry 2011; 72: 126‐ 133. 21382304 PMC3076589
  62. [75]Ismail Z, Smith EE, Geda Y, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement 2016; 12: 195‐ 202. 26096665 PMC4684483
  63. [76]Creese B, Brooker H, Ismail Z, et al. Mild behavioral impairment as a marker of cognitive decline in cognitively normal older adults. Am J Geriatric Psychiatry. 2019; 27(8): 823‐ 834. 30902566
  64. [78]Taragano FE, Allegri RF, Heisecke SL, et al. Risk of conversion to dementia in a mild behavioral impairment group compared to a psychiatric group and to a mild cognitive impairment group. J Alzheimers Dis 2018; 62: 227‐ 238. 29439333
  65. [79]Mortby ME, Ismail Z, Anstey KJ. Prevalence estimates of mild behavioral impairment in a population‐based sample of pre‐dementia states and cognitively healthy older adults. Int Psychogeriatr 2018; 30: 221‐ 232. 28931446
  66. [80]Blackwell T, Yaffe K, Ancoli‐Israel S, et al. Poor sleep is associated with impaired cognitive function in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci 2006; 61: 405‐ 410. 16611709
  67. [81]Miyata S, Noda A, Iwamoto K, Kawano N, Okuda M, Ozaki N. Poor sleep quality impairs cognitive performance in older adults. J Sleep Res 2013; 22: 535‐ 541. 23560612
  68. [82]Jaussent I, Bouyer J, Ancelin ML, et al. Excessive sleepiness is predictive of cognitive decline in the elderly. Sleep 2012; 35: 1201‐ 1207. 22942498 PMC3413797
  69. [83]Spira AP, An Y, Wu MN, et al. Excessive daytime sleepiness and napping in cognitively normal adults: associations with subsequent amyloid deposition measured by PiB PET. Sleep 2018; 41. PMC6289234 30257013
  70. [84]Spira AP, Gamaldo AA, An Y, et al. Self‐reported sleep and beta‐amyloid deposition in community‐dwelling older adults. JAMA Neurol 2013; 70: 1537‐ 1543. 24145859 PMC3918480
  71. [85]Westwood AJ, Beiser A, Jain N, et al. Prolonged sleep duration as a marker of early neurodegeneration predicting incident dementia. Neurology 2017; 88: 1172‐ 1179. 28228567 PMC5373785
  72. [88]Carvalho DZ, St Louis EK, Knopman DS, et al. Association of excessive daytime sleepiness with longitudinal beta‐amyloid accumulation in elderly persons without dementia. JAMA Neurol 2018; 75: 672‐ 680. 29532057 PMC5885188
  73. [89]Escott‐Price V, Myers AJ, Huentelman M, Hardy J. Polygenic risk score analysis of pathologically confirmed Alzheimer disease. Ann Neurol 2017; 82: 311‐ 314. 28727176 PMC5599118
  74. [91]Tan CH, Hyman BT, Tan JJX, et al. Polygenic hazard scores in preclinical Alzheimer disease. Ann Neurol 2017; 82: 484‐ 488. 28940650 PMC5758043
  75. [92]Tan CH, Fan CC, Mormino EC, et al. Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition. Acta Neuropathol 2018; 135: 85‐ 93. 29177679 PMC5758038
  76. [93]Dodge HH, Zhu J, Mattek NC, Austin D, Kornfeld J, Kaye JA. Use of high‐frequency in‐home monitoring data may reduce sample sizes needed in clinical trials. PLoS One 2015; 10: e0138095. 26379170 PMC4574479
  77. [94]Akl A, Chikhaoui B, Mattek N, Kaye J, Austin D, Mihailidis A. Clustering home activity distributions for automatic detection of mild cognitive impairment in older adults. J Ambient Intell Smart Environ 2016; 8: 437‐ 451. 27617044 PMC5016038
  78. [95]Asgari M, Kaye J, Dodge H. Predicting mild cognitive impairment from spontaneous spoken utterances. Alzheimers Dement (N Y) 2017; 3: 219‐ 228. 29067328 PMC5651423
  79. [96]Fraser KC, Meltzer JA, Rudzicz F. Linguistic features identify alzheimer's disease in narrative speech. J Alzheimers Dis 2016; 49: 407‐ 422. 26484921
  80. [97]Berisha V, Wang S, LaCross A, Liss J. Tracking discourse complexity preceding Alzheimer's disease diagnosis: a case study comparing the press conferences of presidents Ronald Reagan and George Herbert Walker Bush. J Alzheimers Dis 2015; 45: 959‐ 963. 25633673 PMC6922000
  81. [98]Kaye J, Reynolds C, Bowman M, et al. Methodology for establishing a community‐wide life laboratory for capturing unobtrusive and continuous remote activity and health Data. J Vis Exp 2018. PMC6126551 30102277
  82. [99]Maruff P, Lim YY, Darby D, et al. AIBL research group. BMC Psychol. 2013; 1(1): 30. 25566378 PMC4269990
  83. [102]Karlawish J. Understanding the impact of learning an amyloid PET scan result: Preliminary findings from the SOKRATES study. Alzheimers Dement 2016; 12: P325.
  84. [103]Weninger S, Carrillo MC, Dunn B, et al. Collaboration for Alzheimer's prevention: principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimers Dement 2016; 12: 631‐ 632. 27157073 PMC5111162

Cited by

Sorted by citations

Authors
McDade, E., Bednar, M. M., Brashear, H. R., Miller, D. S., Maruff, P., Randolph, C., Ismail, Z., Carrillo, M. C., Weber, C. J., Bain, L. J., & Hake, A. M.
Affiliations
  • Washington University in St. Louis (US)
  • Takeda Pharmaceuticals International Co. Americas, Inc. Cambridge Massachusetts USA
  • Janssen Research and Development South San Francisco California USA
  • Signant Health Blue Bell Pennsylvania USA
  • Cogstate Ltd Melbourne Victoria Australia
  • Loyola University Medical Center (US)
  • University of Calgary (CA)
  • Alzheimer's Association Chicago Illinois USA
  • Alzheimer's Association (US)
  • Independent Science Writer Elverson Pennsylvania USA
  • Eli Lilly (United States) (US)
Corresponding author
Weber, Christopher J.
ORCID
Venue
Alzheimer's & Dementia: Translational Research & Clinical Interventions
Publisher
Wiley
Published
2020-01
Volume
6
Issue
1
Pages
e12069-e12069
ISSN
2352-8737 (ISSN-L)
DOI
10.1002/trc2.12069
PMC
PMC7453146
OpenAlex
W3081520742
Cited by
20
References
14
Citations by year
2026: 8 · 2025: 3 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 1
FWCI
1.28
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-nd)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Eli Lilly and Company
  • Eisai
  • Takeda Pharmaceuticals International
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
Alzheimer's disease, secondary prevention, preclinical Alzheimer's disease, drug development, preclinical detection, at-risk individuals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review